Alpha Tau Reports Strong Q1 2026 Data, Advances Key Trials — Alpha Tau Medical Ltd.

Event summary

Alpha Tau's U.S. REGAIN trial in recurrent glioblastoma showed 100% local disease control and 67% complete response rate in initial patients.
Completed patient enrollment in the U.S. pivotal ReSTART trial for recurrent cutaneous squamous cell carcinoma, a critical milestone for FDA approval.
Presented pooled pancreatic cancer trial data at Digestive Disease Week 2026, demonstrating 100% local disease control.
FDA approved an IDE supplement to expand the IMPACT pancreatic cancer trial, adding patients receiving gemcitabine with Abraxane®.
Cash position of $80.2 million provides runway for continued clinical advancement and commercial preparation.

The big picture

Alpha Tau's Q1 2026 results highlight significant progress in its clinical pipeline, particularly in hard-to-treat cancers like glioblastoma and pancreatic cancer. The company's strategic focus on both U.S. and Japanese regulatory pathways positions it to capitalize on unmet needs in oncology. With a strong cash position, Alpha Tau is well-equipped to navigate the next phases of clinical development and potential commercialization.

What we're watching

Clinical Efficacy: How the 100% local disease control rates in glioblastoma and pancreatic cancer trials will impact regulatory discussions and investor confidence.
Regulatory Pathway: Whether the completion of the ReSTART trial enrollment will accelerate FDA approval timelines for Alpha DaRT in cutaneous squamous cell carcinoma.
Commercialization: The pace at which Alpha Tau can transition from clinical trials to commercialization, particularly in Japan where it has already received PMDA approval.